AptarGroup Inc

ATR: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$672.00BwjdwtQndhpfbn

Aptar's Pharma Business Drives Growth; We Maintain Our $132 Fair Value Estimate, Shares Undervalued

Narrow-moat Aptar delivered solid fourth-quarter and full-year results driven primarily by its Pharma business and volume growth in beauty and home. Full-year 2022 results are in line with our assumptions, and we are maintaining our $132 fair value estimate. Shares appear undervalued.

Sponsor Center